Ratings for Stryker SYK were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding ...

Adjusted Effective Tax Rate: 13.7% for Q1 2025. Stryker Corp (NYSE:SYK) reported robust organic sales growth of 10.1% in Q1 2025, with strong performances in MedSurg, neurotechnology, and orthopedics.

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Stryker expects a $200 million hit to its 2025 earnings from tariffs, the latest medical device company to call out impacts of hundreds of millions of dollars. CFO Preston Wells told investors ...

Forecast issued at 4:15 pm CST on Thursday 8 May 2025.